|Bid||0.2000 x 0|
|Ask||0.2050 x 0|
|Day's Range||0.2000 - 0.2100|
|52 Week Range||0.1050 - 0.6900|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
TORONTO, ON and NEW YORK, NY / ACCESSWIRE / June 29, 2020 / Eyecarrot Innovations Corp., (Eyecarrot) (EYC.V)(EYCCF)(2EYA:GR) a leader is neuro-vision performance technology, announces that its Board of Directors has approved a name change from Eyecarrot Innovations Corp. to Binovi Technologies Corp. In connection with the name change, the Company's trading symbol on the TSX Venture Exchange ("TSXV") will be changed to 'VISN'. It is expected that the name change will be effected on or about June 30, 2020 and the Company's common shares will begin trading under the new name and symbol upon market open on Thursday July 2, 2020, subject to final approval by TSXV.
TORONTO, ON and NEW YORK, NY / ACCESSWIRE / June 11, 2020 / Eyecarrot Innovations Corp (TSXV:EYC)(EYCCF)(2EYA:GR is pleased to announce the appointment of Dr. Jason Dyck and the appointment of Dr. Sandra Stoddard to the company's Scientific Advisory Board. Dr. Jason Dyck is a world-class research scientist and professor in the Department of Pediatrics at the University of Alberta, the director of the University of Alberta Cardiovascular Research Centre, a Canada Research Chair in Molecular Medicine, and a fellow of the Canadian Academy of Health Sciences.
TORONTO, ON and NEW YORK, NY / ACCESSWIRE / June 9, 2020 / Eyecarrot Innovations Corp (EYC.V)(EYCCF)(FRA:2EYA:GR) is pleased to announce the closing of the previously announced non-brokered private placement for total proceeds of C$1 million. The Company issued a total of 7,843,137 units at C$0.1275 per unit, each unit comprised of one common share of the Company (a "Share") and one common share purchase warrant (a "Warrant"). The warrants are subject to an acceleration clause whereby if the common share price is equal to or greater than C$0.50 for a period of 5 consecutive trading days (at any time at or following the expiry of the four months resale restriction period), the Company may, by notice to the warrant holder reduce the remaining exercise period applicable to the warrants to not less than 30 days from the date of such notice.